Lucid Diagnostics

Lucid Diagnostics, Inc. develops medical testing devices. It is a commercial-stage medical diagnostics technology company which focuses on gastroesophageal reflux disease (GERD), acid reflux or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically lethal esophageal adenocarcinoma (EAC). The firm's products include EsoCheck is a cell collection device that is designed to collect cells of a targeted region of the esophagus without the need for endoscopy and EsoGuard is a laboratory developed test which analyzes methylated biomarkers. The company was founded on May 8, 2018 and is headquartered in New York, NY.

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Lucid Diagnostics excels in Q4, eyes growth through precancer detection

Lucid Diagnostics (LUCD) demonstrated robust performance in Q4 2022, focusing on growth, financial stability, and strategic initiatives for precancer detection.
The company's strengths lie in strong revenue potential, innovative testing models, and a proactive approach to securing payer coverage and expanding its market reach.
While facing challenges in cash management and sales team tenure, Lucid Diagnostics has opportunities to drive growth through geographic expansion, high-risk group engagement, and data-driven payer strategies.

Lucid Diagnostics reports robust Q1 performance and growth opportunities

Lucid Diagnostics showed strong performance with increased tests and financial security in Q1 2023.
The company's focus on early precancer detection and large target market are key strengths.
Challenges include improving payment collections and securing in-network contracts.
Opportunities lie in expanding outreach efforts and engaging with payers for coverage.

Lucid Diagnostics reports robust Q2 performance and eyes sustained growth

Lucid Diagnostics delivered a strong Q2 performance with notable revenue growth and operational improvements.
While facing challenges in revenue recognition and payer engagement, the company's focus on clinical utility studies and high-volume events presents growth opportunities.
With a solid financial position and a strategic approach to market access, Lucid is poised for sustained growth and increased market penetration.

Lucid Diagnostics (LUCD) reports stellar Q3 growth and eyes market expansion

Lucid Diagnostics (LUCD) demonstrated strong performance in Q3 2023, marked by substantial revenue and test volume growth. The company's strategic initiatives, financial stability, and focus on market access position it for continued success. While challenges in managing expenses persist, Lucid's opportunities for expansion and engagement with key stakeholders pave the way for future growth and profitability.

Lucid Diagnostics reports stellar Q4 results and eyes market expansion

Lucid Diagnostics (LUCD) showcased robust financial performance and strategic initiatives in Q4 2023, driving revenue growth and market expansion.
While facing challenges such as significant operating expenses and uncertainties in reimbursement processes, Lucid is well-positioned to capitalize on opportunities for revenue realization and market access.
With a focus on clinical validity, engagement with payers, and exclusive product rights, Lucid demonstrates a strong competitive advantage and potential for sustained growth in the diagnostic market.

Lucid Diagnostics excels in Q1 2024, poised for market expansion

Lucid Diagnostics delivered strong financial performance in Q1 2024, showcasing revenue growth, robust margins, and a strengthened balance sheet.
The company's focus on market access strategies, innovative diagnostics, and revenue cycle improvements positions them for future success.
While facing challenges such as pending adjudications and international expansion limitations, Lucid is well-positioned to capitalize on opportunities in healthcare partnerships and market awareness.
Overall, Lucid's commitment to driving commercial potential and enhancing cancer detection technologies underpins their growth trajectory and shareholder value creation.

Lucid Diagnostics reports robust revenue growth and navigates reimbursement challenges

Lucid Diagnostics demonstrated strong revenue growth momentum driven by record test volumes and positive clinical data.
While facing reimbursement challenges, the company's proactive approach to market access and partnerships positions them for future success.
Maintaining a healthy cash position and focusing on operational efficiency are key strengths that support Lucid's growth trajectory.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Lucid Diagnostics, Inc. is a commercial-stage medical diagnostics technology company. It focuses on patients with gastroesophageal reflux disease also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically highly lethal esophageal adenocarcinoma. The company was founded by Lishan Aklog on May 8, 2018 and is headquartered in New York, NY.

PAVmed

EsoGuard® test volume gains momentum as Lucid expands high-volume testing events PAVmed appoints President for Veris Health and expands commercial footprint Conference call and webcast to be held tomorrow, May 17 th at 8:30 AM EST NEW YORK , May 16, 2023 /PRNewswire/ -- PAVmed Inc.  (NASDAQ: PAVM, PAVMZ) ("PAVmed" or the "Company"), a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital health sectors, today provided a business update for the Company and its subsidiaries, Lucid Diagnostics Inc. (NASDAQ: LUCD) ("Lucid") and Veris Health Inc. ("Veris"), and presented financial results for the Company for the three months ended March 31, 2023. Conference Call and Webcast The webcast will take place on Wednesday, May 17, 2023, at 8:30 AM and will be accessible in the investor relations section of the Company's website at pavmed.com.

PAVmed Provides Business Update and First Quarter Financial Results

EsoGuard® test volume increases 57 percent sequentially and 245 percent year-on-year Conference call and webcast to be held tomorrow, May 16 th at 8:30 AM EST NEW YORK , May 15, 2023 /PRNewswire/ --  Lucid Diagnostics Inc.  (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM, PAVMZ) ( "PAVmed"), today provided a business update for the Company and presented financial results for the three months ended March 31, 2023. Conference Call and Webcast The webcast will take place on Tuesday, May 16, 2023, at 8:30 AM and will be accessible in the investor relations section of the Company's website at luciddx.com.

Lucid Diagnostics Provides Business Update and First Quarter Financial Results

EsoGuard® continues to demonstrate excellent esophageal precancer and cancer detection performance, including in most prevalent and challenging precancer subgroup—short segment non-dysplastic Barrett's Esophagus EsoCheck® cell collection performed with 98 percent technical success and high DNA yields in real-world study of 1483 patients NEW YORK , May 11, 2023 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM, PAVMZ) ("PAVmed"), today announced findings from two clinical studies of its EsoGuard® Esophageal DNA Test and EsoCheck® Cell Collection Device, presented at this week's Digestive Disease Week (DDW) 2023 conference—the world's premier meeting for digestive disease professionals. "We are excited that Lucid had a strong presence and it's technologies garnered widespread interest at this year's DDW conference," said Suman Verma, M.D.

Lucid Diagnostics and Collaborators Present New EsoGuard® and EsoCheck® Data at Digestive Disease Week® (DDW) 2023 Conference

Conference Call and Webcast at 8:30AM Eastern Time NEW YORK , May 5, 2023 /PRNewswire/ -- Lucid Diagnostics Inc.  (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company and majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM, PAVMZ), today announced that it will host a business update conference call and webcast on Tuesday, May 16, 2023, at 8:30 AM EST. During the call,  Lishan Aklog, M.D.

Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on May 16, 2023

Lucid Diagnostics Reports Publication of Future Effective Foundational Local Coverage Determination by Medicare Administrative Contractor Noridian Healthcare Solutions

NEW YORK, April 17, 2023 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company and majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM, PAVMZ) ("PAVmed"), today announced that Dr. Lishan Aklog, Chairman and Chief Executive Officer; and Dennis McGrath, Chief Financial Officer will present at the 22nd Annual Needham Healthcare Conference on Thursday, April 20, 2023 at 11:00 AM ET.

Lucid Diagnostics to Present at 22nd Annual Needham Virtual Healthcare Conference

Foundational LCD, to be effective May 14, 2023, incorporates key feedback to 2022 draft, including updated guidelines recommending non-endoscopic biomarker testing Lucid positioned to submit EsoGuard for Technical Assessment and coverage under foundational LCD when sufficient clinical utility data available later this year NEW YORK , March 31, 2023 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid Diagnostics" or "Lucid"), a commercial-stage cancer prevention diagnostics company and a majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM, PAVMZ), announced that, yesterday, the MolDX Program ("MolDX") published a Future Effective Local Coverage Determination ("LCD") L39256, on molecular testing for esophageal precancer and cancer in Medicare beneficiaries, to become effective May 14, 2023. This foundational LCD, entitled "Molecular Testing for Detection of Upper Gastrointestinal Metaplasia, Dysplasia, and Neoplasia" and published on CMS.gov, provides the criteria for future coverage of individual tests within this category, such as Lucid's EsoGuard® Esophageal DNA Test, following submission of each test for Technical Assessment.

Lucid Diagnostics Provides Update on Newly Published Future Effective Medicare Local Coverage Determination on Molecular Testing for Detection of Esophageal Precancer and Cancer

Lucid Group

Lucid CEO Peter Rawlinson said the job cuts will hit "nearly every organization and level, including executives."

Lucid to cut 1,300 workers amid signs of flagging demand for its EVs

Lucid Diagnostics Inc. (NASDAQ:LUCD ) Q4 2022 Earnings Conference Call March 14, 2023 8:30 AM ET Company Participants Michael Parks - Vice President, Investor Relations Dr. Lishan Aklog - Chairman and CEO Dennis McGrath - Chief Financial Officer Conference Call Participants Kyle Mikson - Canaccord Genuity Ross Osborn - Cantor Fitzgerald Mike Matson - Needham & Co. Mark Massaro - BTIG Edward Woo - Ascendiant Capital Operator Welcome to the Lucid Diagnostics Business Update and Fourth Quarter 2022 Financial Results Conference Call. At this time, all participants will be in a listen-only mode.

Lucid Diagnostics Inc. (LUCD) Q4 2022 Earnings Call Transcript

4Q22 and projected 1Q23 EsoGuard® test volume increases 8 and 36 percent sequentially and 288 and 300 percent annually. Company signs in-network agreement with largest secondary PPO, MultiPlan, expanding patient access to EsoGuard.

Lucid Diagnostics Provides Business Update and Fourth Quarter and Full Year 2022 Financial Results

Conference Call and Webcast at 8:30AM Eastern Time NEW YORK , March 3, 2023 /PRNewswire/ -- Lucid Diagnostics Inc.  (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company and majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM, PAVMZ), today announced that it will host a business update conference call and webcast on Tuesday, March 14, 2023, at 8:30 AM EST. During the call,  Lishan Aklog, M.D.

Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on March 14, 2023

NEW YORK--( BUSINESS WIRE )--PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (“PAVmed”), a diversified commercial-stage medical technology company operating in the medical device, diagnostics, and digital health sectors, and its majority-owned subsidiaries Lucid Diagnostics Inc. (Nasdaq: LUCD) (“Lucid” or “Lucid Diagnostics”), a commercial-stage cancer prevention diagnostics company, and Veris Health Inc. (“Veris”), a private digital health company focused on enhanced personalized cancer care, today provided a strategic business update, outlining near-term strategic priorities and resource reallocation. The companies will prioritize near-term Lucid and Veris Health commercialization efforts. They have implemented a workforce reduction of approximately 20 percent, product portfolio streamlining, and other cost-cutting measures which seek to lower quarterly cash burn by at least 25 percent.

PAVmed and Lucid Diagnostics Provide Strategic Business Update

NEW YORK--( BUSINESS WIRE )--PAVmed Inc. (Nasdaq: PAVM, PAVMZ), a diversified commercial-stage medical technology company operating in the medical device, diagnostics, and digital health sectors, and its majority-owned subsidiaries Lucid Diagnostics Inc. (Nasdaq: LUCD), a commercial-stage cancer prevention diagnostics company, and Veris Health Inc., a digital health company focused on enhanced personalized cancer care, today announced they will hold a joint conference call to provide a strategic business update on Tuesday, January 17, 2023 at 4:30PM EDT.

PAVmed and Lucid Diagnostics to Provide Strategic Business Update

NEW YORK--( BUSINESS WIRE )-- Lucid Diagnostics Inc. (Nasdaq: LUCD) (“Lucid” or the “Company”), a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (“PAVmed”), today announced that the Company was selected as one of ten finalists for the Medtech Company of the Year 2022 by Medical Device + Diagnostic Industry (“MD+DI”), a leading publication serving manufacturers of medical devices and in vitro diagnostics products, as well as medical technology professionals, for the past forty years.

Lucid Diagnostics Selected as Finalist for Medtech Company of the Year 2022 by Medical Device + Diagnostic Industry

NEW YORK--( BUSINESS WIRE )--Lucid Diagnostics Inc. (Nasdaq: LUCD) (“Lucid”), a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (“PAVmed”), today announced that Suman M. Verma, M.D., Ph.D., Lucid's Chief Scientific Officer, presented real-world data on its EsoCheck® Cell Collection Device (“EsoCheck”) at the American Association for Cancer Research's (“AACR”) Special Conference: Precision Prevention, Early Detection, and Interception of Cancer.

Lucid Diagnostics Presents Real-World EsoCheck Data at the American Association for Cancer Research

NEW YORK--( BUSINESS WIRE )-- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital health sectors, today provided a business update for the Company and its subsidiaries, Lucid Diagnostics Inc. (Nasdaq: LUCD) (“Lucid”) and Veris Health Inc. (“Veris”), and presented financial results for the three and nine months ended September 30, 2022.

PAVmed Provides Business Update and Third Quarter 2022 Financial Results

Lucid Diagnostics Inc. (NASDAQ:LUCD ) Q3 2022 Earnings Conference Call November 14, 2022 4:30 PM ET Company Participants Adrian Miller - Vice President-Investor Relations Lishan Aklog - Chairman & Chief Executive Officer Dennis McGrath - Chief Financial Officer Conference Call Participants Mike Matson - Needham & Company Ross Osborn - Cantor Fitzgerald Ed Woo - Ascendiant Capital Greetings, and welcome to Lucid Diagnostics Third Quarterly Update Conference Call and Webcast. At this time, all participants are in a listen-only mode.

Lucid Diagnostics Inc. (LUCD) Q3 2022 Earnings Call Transcript

NEW YORK--( BUSINESS WIRE )--Lucid Diagnostics Inc. (Nasdaq: LUCD) (“Lucid” or the “Company”), a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (“PAVmed”), today provided a business update for the Company and presented financial results for the three and nine months ended September 30, 2022.

Lucid Diagnostics Provides Business Update and Third Quarter 2022 Financial Results

NEW YORK--(BUSINESS WIRE)-- #CheckYourFoodTube--Lucid Diagnostics Inc. (Nasdaq: LUCD) (“Lucid”, the “Company”), a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (“PAVmed”), today announced that Lishan Aklog, M.D.

Lucid Diagnostics to Participate in Canaccord Genuity's MedTech, Diagnostics and Digital Health & Services Forum

NEW YORK--(BUSINESS WIRE)-- #CheckYourFoodTube--Lucid Diagnostics Inc. (Nasdaq: LUCD) (“Lucid”, the “Company”), a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (“PAVmed”), today announced the commencement of production of its EsoCheck® Esophageal Cell Collection Devices (“EsoCheck”) at Coastline International, Inc. (“Coastline”), a high-volume manufacturer headquartered in San Diego, CA with plants in Mexico.

Lucid Diagnostics Commences Production of EsoCheck Devices with High-Volume Manufacturer

NEW YORK--(BUSINESS WIRE)-- #CheckYourFoodTube--Lucid Diagnostics Inc. (Nasdaq: LUCD) (“Lucid”) a commercial-stage, cancer prevention medical diagnostics company, a majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM, PAVMZ), today announced that the Company will host a business update conference call and webcast on Monday, November 14, 2022, at 4:30 PM EDT.

Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on November 14, 2022

NEW YORK--(BUSINESS WIRE)---- $LUCD #LUCD--PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital health sectors, today provided a business update for the Company and its subsidiaries, Lucid Diagnostics Inc. (Nasdaq: LUCD) (“Lucid”) and Veris Health Inc. (“Veris”), and presented financial results for the three and six months ended June 30, 2022. Conference Call and Webcast A conference c

PAVmed Provides Business Update and Preliminary Second Quarter 2022 Financial Results

Lucid Diagnostics Inc. (NASDAQ:LUCD ) Q2 2022 Earnings Conference Call August 15, 2022 4:30 PM ET Company Participants Adrian Miller - Vice President-Investor Relations Lishan Aklog - Chairman & Chief Executive Officer Dennis McGrath - Chief Financial Officer Conference Call Participants Ross Osborn - Cantor Fitzgerald Mike Matson - Needham & Company Ed Woo - Ascendiant Capital Mark Massaro - BTIG Operator Greetings, and welcome to Lucid Diagnostics Second Quarter 2020 Business Update Conference Call. At this time, all participants are in a listen-only mode.

Lucid Diagnostics Inc. (LUCD) CEO Lishan Aklog on Q2 2022 Results - Earnings Call Transcript

NEW YORK--(BUSINESS WIRE)---- $LUCD #investing--Lucid Diagnostics Provides Business Update and Preliminary Second Quarter 2022 Financial Results

Lucid Diagnostics Provides Business Update and Preliminary Second Quarter 2022 Financial Results

NEW YORK--(BUSINESS WIRE)---- $LUCD #checkyourfoodtube--Lucid Diagnostics Inc. announced its subsidiary, LucidDx Labs Inc., launched four new Lucid Test Centers in California, Texas Florida and Ohio.

News for Lucid Diagnostics Stock (LUCD)